ABOUT US Transmutex is a Swiss company founded in 2019. Transmutex is currently advancing the HI-BEAM (High Intensity Breakthrough Engineering for Advanced Medicine) project, an ambitious programme to develop an industrial-scale facility for the reliable production of medical-grade Actinium-225 (Ac-225), a critical radionuclide for emerging targeted alpha therapies. Our team spans nuclear physics, engineering, software, radiochemistry, pharmaceutical and industrial development. Working wit
Neutral 2–4 sentence summary of what working at this company is like, drawn from public reviews and press coverage. Tone, collaboration style, pace, benefits highlights.
£45,000 – £60,000 (Glassdoor, Levels.fyi, 2025)
